ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT07567846

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

Sponsor

Genentech, Inc.

Enrollment

260 participants

Start Date

Apr 29, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Prostate CancerMetastatic Prostate Cancer

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GDC-1261 for people with advanced prostate cancer and metastatic prostate cancer. The study is currently recruiting participants at 4 locations. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGDC-1261

Participants will receive GDC-1261 as per the schedule described in the protocol.

Locations(4)

Honor Health Research Institute

Scottsdale, Arizona, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Austin Hospital

Heidelberg, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07567846

Related Trials

Collection of Blood From Patients With Prostate Cancer

NCT009232211 location

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

NCT054041392 locations

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

NCT0501138317 locations

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

NCT063692461 location

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

NCT072527263 locations